Understanding how a specific receptor affects skin fibrosis
Epidermal Growth Factor Receptor Signaling in Fibrotic Skin Disease
This study is looking at how a specific protein in skin cells might contribute to thickening and scarring of the skin in conditions like scleroderma or after stem cell transplants, with the hope of finding new ways to help people with these skin issues feel better.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project ID | NIH-10862668 on NIH RePORTER |
What this research studies
This research investigates the role of epidermal growth factor receptor (EGFR) signaling in the development of fibrotic skin diseases, which can arise from autoimmune conditions like scleroderma or after stem cell transplants. The study aims to identify the cellular signals activated by EGFR in skin cells and how these signals interact with other pathways involved in fibrosis. By examining these mechanisms, the research seeks to uncover potential targets for new treatments that could alleviate or prevent fibrosis in affected patients.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals suffering from fibrotic skin diseases, particularly those with autoimmune conditions like scleroderma or those who have undergone stem cell transplants.
Not a fit: Patients with non-fibrotic skin conditions or those without chronic inflammatory diseases may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that reduce or prevent skin fibrosis, improving quality of life for patients with chronic inflammatory diseases.
How similar studies have performed: Previous research has shown promising results in targeting EGFR signaling in other fibrotic conditions, suggesting that this approach may be effective in treating skin fibrosis as well.
Where this research is happening
New Haven, United States
- Yale University — New Haven, United States (Active)
Researchers
- Principal investigator: Odell, Ian D — Yale University
- Study coordinator: Odell, Ian D
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.